Improvements in Physical Function and Pain Relief Were Sustained in Rheumatoid Arthritis Patients Treated for 2 Years with Certolizumab Pegol

被引：0
|
作者：
Bykerk, Vivian [1 ]
Mease, Philip [2 ]
Coteur, Geoffroy
Keininger, Dorothy
机构：
[1] Mt Sinai Hosp, Toronto, ON, Canada
[2] Seattle Rheumatol Associates, Seattle, WA USA
来源：
JOURNAL OF RHEUMATOLOGY | 2009年 / 36卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
19
引用
收藏
页码：2567 / 2567
页数：1
相关论文
共 50 条
  • [31] CERTOLIZUMAB PEGOL PROVIDES SUSTAINED REMISSION AND MINIMAL DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS OVER 4 YEARS' TREATMENT
    van der Heijde, D.
    Deodhar, A.
    FitzGerald, O.
    Fleischmann, R.
    Gladman, D.
    Gottlieb, A. B.
    Coates, L. C.
    Hoepken, B.
    Bauer, L.
    Peterson, L.
    Khraishi, M.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1027 - 1027
  • [32] IDENTIFICATION OF TIME-DEPENDENT RISK FACTORS FOR SERIOUS INFECTIOUS EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
    Curtis, J. R.
    de Longueville, M.
    O'Brien, C.
    Haraoui, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 705 - 705
  • [33] EFFECTS OF DIFFERENT STEROID DOSES ON ADVERSE EVENTS AND RADIOGRAPHIC PROGRESSION OF CERTOLIZUMAB PEGOL-TREATED RHEUMATOID ARTHRITIS PATIENTS
    Haraoui, B.
    Combe, B.
    Champsaur, M.
    Luijtens, K.
    Keystone, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 498 - 498
  • [34] Risk of Lymphoma in Rheumatoid Arthritis (RA) Patients Treated with Certolizumab Pegol (CZP) Compared to World and US General Populations
    Guo, Jennifer D.
    Golembesky, Amanda
    Rosario-Jansen, Theresa
    Miller, David P.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 437 - 437
  • [35] Comparative analysis of low-field magnetic resonance imaging in patients with rheumatoid arthritis treated with certolizumab pegol or infliximab
    Hagiwara, Shinya
    Tsuboi, Hiroto
    Kuroda, Yuki
    Sawabe, Tomonori
    Uematsu, Nana
    Kawashima, Fumina
    Sugita, Toshiki
    Terasaki, Mayu
    Honda, Fumika
    Yagishita, Mizuki
    Kondo, Yuya
    Sumida, Takayuki
    Matsumoto, Isao
    MODERN RHEUMATOLOGY, 2023, 33 (06) : 1097 - 1103
  • [36] DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA
    Bykerk, V.
    Gottlieb, A. B.
    Reich, K.
    Tanaka, Y.
    Winthrop, K.
    Popova, C.
    Tilt, N.
    Blauvelt, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 617 - 617
  • [37] Concordance Between the Patient, Nurse and Physician Assessment of Clinical Outcomes in a Cohort of Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
    Inderjeeth, Charles
    Inderjeeth, Andrisha
    Raymond, Warren
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [38] Certolizumab pegol added onto methotrexate improves physical functioning and reduces pain in patients with rheumatoid arthritis who have an incomplete response to methotrexate: Data from rapid 2
    Schiff, M.
    Keininger, D. L.
    Tahiri-Fitzgerald, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 187 - 187
  • [39] Abatacept provides sustained improvements in pain, fatigue and sleep quality through 2 years in the treatment of rheumatoid arthritis patients in the aim and attain trials
    Dougados, M.
    Russell, Anthony
    Li, Tracy
    Sherrer, Y.
    Teng, J.
    McCann, T.
    Westhovens, R.
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1629 - 1629
  • [40] Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study
    Saraux, A.
    Combe, B.
    Fagnani, F.
    Cukierman, G.
    Bru, I
    Joubert, J-M
    Schuller, J-C
    Massol, J.
    Flipo, R-M
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (04) : 781 - 789
12345